Zimmer (ZBH) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates

Core Insights - Zimmer Biomet reported $2.02 billion in revenue for Q4 2024, a year-over-year increase of 4.3% and an EPS of $2.31, up from $2.20 a year ago, exceeding Zacks Consensus Estimates for both revenue and EPS [1] Financial Performance - Revenue of $2.02 billion surpassed the Zacks Consensus Estimate of $2.01 billion, resulting in a surprise of +0.53% [1] - EPS of $2.31 compared to the consensus estimate of $2.30, yielding a surprise of +0.43% [1] Key Metrics - Net Sales for Knees in International markets reached $349.10 million, exceeding the average estimate of $346.83 million, with a year-over-year change of +6.8% [4] - Net Sales for Hips in International markets were $248.30 million, slightly below the average estimate of $251.75 million, reflecting a year-over-year change of +2.8% [4] - Net Sales for Knees in the United States totaled $490.10 million, surpassing the average estimate of $487.71 million, with a year-over-year change of +3.9% [4] - Net Sales for Hips in the United States were $271.70 million, below the average estimate of $275.82 million, showing a year-over-year change of +3.2% [4] - Total Net Sales in the United States reached $1.18 billion, exceeding the average estimate of $1.16 billion, with a year-over-year change of +4.7% [4] - International Net Sales amounted to $842 million, slightly below the average estimate of $845.46 million, with a year-over-year change of +3.7% [4] - Overall Net Sales for Knees were $839.20 million, slightly above the average estimate of $837.55 million, reflecting a +5.1% change year-over-year [4] - Net Sales for Other products were $174.60 million, exceeding the average estimate of $172.36 million, but showing a year-over-year decline of -5% [4] - Net Sales for S.E.T. reached $489.40 million, surpassing the average estimate of $474.56 million, with a year-over-year change of +8% [4] - Net Sales for Hips totaled $520 million, slightly below the average estimate of $524.38 million, with a year-over-year change of +3% [4] Stock Performance - Zimmer's shares returned +6.6% over the past month, outperforming the Zacks S&P 500 composite's +2.1% change [3] - The stock currently holds a Zacks Rank 4 (Sell), indicating potential underperformance relative to the broader market in the near term [3]